SCHEMBL72610

SCHEMBL72610

O=c1c(-c2ccc(O)cc2O)coc2cc(O)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.72
ALDH1A1 P00352 9/20 0.72
SMN1; SMN2 Q16637 5/20 0.72
NPC1 O15118 5/20 0.72
RAB9A P51151 5/20 0.72
POLB P06746 3/20 0.72
NPSR1 Q6W5P4 1/20 0.72
HSD17B10 Q99714 9/20 0.71
HPGD P15428 8/20 0.71
MAPT P10636 6/20 0.71
CYP3A4 P08684 4/20 0.71
TP53 P04637 3/20 0.71
TDP1 Q9NUW8 2/20 0.71
CYP2D6 P10635 2/20 0.71
CYP2C9 P11712 2/20 0.71
MAOA P21397 2/20 0.71
MAOB P27338 2/20 0.71
CYP2C19 P33261 2/20 0.71
HDAC6 Q9UBN7 2/20 0.71
CA12 O43570 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31134786 1.00 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL29737520 1.00 KDM4E (0.72) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL232753 0.90 KDM4E (0.74) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL27869009 0.90 KDM4E (0.68) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL72628 0.88 KDM4E (0.70) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
Xenognosin B SCHEMBL72611 0.87 KDM4E (0.83) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
Xenognosin B SCHEMBL30851576 0.87 KDM4E (0.83) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
7-Hydroxy Isoflavone SCHEMBL762528 0.84 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
Daidzein SCHEMBL21114371 0.83 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
Daidzein SCHEMBL29374778 0.83 KDM4E (1.00) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US claimed
US-20150290271-A1 Nutraceutical Composition Obtained from Fungus-Challenged Soy Seedlings FRUTAROM SWITZERLAND LTD. (CH) 2015-10-15 US claimed
EP-2592951-A1 NUTRACEUTICAL COMPOSITION OBTAINED FROM FUNGUS-CHALLENGED SOY SEEDLINGS Frutarom Switzerland Ltd (CH) 2013-05-22 EP claimed
WO-2012006750-A1 NUTRACEUTICAL COMPOSITION OBTAINED FROM FUNGUS-CHALLENGED SOY SEEDLINGS FRUTAROM SWITZERLAND LTD. (CH) 2012-01-19 WO claimed
US-20020177527-A1 Methods for the identification of inhibitors of 2'-hydroxyisoflavone reductase expression or activity in plants ICORIA, INC. 2002-11-28 US claimed
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities THE BROAD INSTITUTE, INC. (US) 2026-03-17 US disclosed
US-20250376656-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-11 US disclosed
WO-2025049925-A2 LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES POSEIDA THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
US-20250051551-A1 IMPROVED POLYMER COMPOSITES WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2025-02-13 US disclosed
US-12163004-B2 Polymer composites WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2024-12-10 US disclosed
US-20240355451-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY NESTLE SA (CH) 2024-10-24 US disclosed
EP-4391834-A1 METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY Société des Produits Nestlé S.A. (CH) 2024-07-03 EP disclosed
EP-0948602-A1 RECOMBINANT PINORESINOL/LARICIRESINOL REDUCTASE, RECOMBINANT DIRIGENT PROTEIN, AND METHODS OF USE WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 1999-10-13 EP disclosed
EP-0866710-A1 COMPOSITIONS AND METHODS FOR TREATING BONE DEFICIT CONDITIONS ZymoGenetics, Inc. (US) 1998-09-30 EP disclosed
WO-1998020113-A1 RECOMBINANT PINORESINOL/LARICIRESINOL REDUCTASE, RECOMBINANT DIRIGENT PROTEIN, AND METHODS OF USE WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 1998-05-14 WO disclosed
US-5750399-A CONTROL TRANSCRIPTION IN PLANTS THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 1998-05-12 US disclosed
EP-0792356-A1 ISOFLAVONE REDUCTASE PROMOTER The Samuel Roberts Noble Foundation, Inc. (US) 1997-09-03 EP disclosed
WO-1997015308-A9 COMPOSITIONS AND METHODS FOR TREATING BONE DEFICIT CONDITIONS 1997-06-26 WO disclosed
WO-1997015308-A1 COMPOSITIONS AND METHODS FOR TREATING BONE DEFICIT CONDITIONS ZYMOGENETICS, INC. (US) 1997-05-01 WO disclosed
WO-1996015239-A2 ISOFLAVONE REDUCTASE PROMOTER THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 1996-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities STUB1, SAMM50, CD14 KDM4E 2737/4885ALDH1A1 1629/4885SMN1; SMN2 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.